title: Role of antinuclear antibodies in experimental and clinical liver transplantation.
abstract: OBJECTIVE
  We recently reported that autoreactive antibodies (Abs) against nuclear histone H1 was transiently induced at an early phase after orthotopic liver transplantation (OLT) in a tolerogenic rat OLT model and possessed immunosuppressive activity. It was also reported that nuclear antigen, high-mobility group box 1 (HMGB1) protein was one of the initiators of the immune reaction. The present study sought to evaluate the role of antinuclear Abs in experimental and clinical liver transplantation.
  
  
  METHODS
  We prepared 3 animal models: natural tolerance model (DA liver into PVG); acute rejection model (DA liver into LEW); and drug-induced tolerance model (acute rejection model + cyclosporine [CsA]). In addition, we examined clinical samples, including 1 drug-free patient, to measure the antihistone H1/HMGB1 titers at various times after OLT.
  
  
  RESULTS
  In a natural tolerance model, antihistone H1 and HMGB1 Ab was induced during the rejection and the tolerance induction phases, respectively. Those Ab responses were also confirmed in a drug-induced tolerance model, whereas no such responses were shown in an acute rejection model. In our clinical drug-free patient, antihistone H1/HMGB1 titer was significantly higher after cessation of CsA than that in healthy volunteers.
  
  
  CONCLUSIONS
  Antinuclear Ab is actively expressed in accordance with overcoming rejection episodes with subsequent tolerance induction in both a natural tolerance model and a drug-induced tolerance model. We also observed a similar tendency in our clinical drug-free patient. These results suggested that antinuclear Abs may be useful markers to determine the timing to withdraw immunosuppressants.
authors.affiliation: Department of Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan.
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: C-Y
authors.initials: CY
authors.lastname: Lai
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: L-W
authors.initials: LW
authors.lastname: Hsu
authors.forename: Y-C
authors.initials: YC
authors.lastname: Lin
authors.forename: Y-H
authors.initials: YH
authors.lastname: Kao
authors.forename: S
authors.initials: S
authors.lastname: Kawamoto
authors.forename: K-C
authors.initials: KC
authors.lastname: Chiang
authors.forename: N
authors.initials: N
authors.lastname: Ohmori
authors.forename: T
authors.initials: T
authors.lastname: Goto
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Ono
authors.forename: B
authors.initials: B
authors.lastname: Jawan
authors.forename: Y-F
authors.initials: YF
authors.lastname: Cheng
authors.forename: C-L
authors.initials: CL
authors.lastname: Chen
mesh_terms: D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood*; D001323:Autoantibodies / Q000097:blood; D004195:Disease Models, Animal; D006801:Humans; D007108:Immune Tolerance; D016031:Liver Transplantation / Q000276:immunology*; D051381:Rats; D011917:Rats, Inbred Lew
chemical_list: D000974:Antibodies, Antinuclear; D001323:Autoantibodies